Abstract |
A controlled cross-over study with transfer factor was carried out on 7 patients suffering from chronic mucocutaneous candidiasis. Only one patient showed clinical improvement, which started during a period of pretreatment with 5-fluorocytosine given orally 14 days before the patient entered this trial. No conversion to a positive skin test with Candida antigen or PPD was demonstrated following TF in the 6 patients who were anergic to either of these antigens. Variations in the cell-mediated immune response as revealed by lymphocyte transformation were observed in most patients, especially when studied over a long period of time. However, no pronounced efficacy of TF vis-à-vis placebo in normalizing the cell-mediated immune response could be demonstrated in the 5 patients who completed the clinical trial. Systemic side effects were not observed.
|
Authors | H Mobacken, L A Hanson, L Lindholm, C Ljunggren |
Journal | Acta dermato-venereologica
(Acta Derm Venereol)
Vol. 60
Issue 1
Pg. 51-5
( 1980)
ISSN: 0001-5555 [Print] Sweden |
PMID | 6153834
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Placebos
- Transfer Factor
- Flucytosine
|
Topics |
- Adolescent
- Adult
- Candidiasis, Cutaneous
(drug therapy, immunology, therapy)
- Child
- Child, Preschool
- Chronic Disease
- Clinical Trials as Topic
- Double-Blind Method
- Female
- Flucytosine
(therapeutic use)
- Humans
- Male
- Mucous Membrane
(pathology)
- Placebos
- Skin Tests
- Transfer Factor
(therapeutic use)
|